BMS cuts 4,800 jobs

The long-awaited details on Bristol-Myers Squibb's job cuts have finally arrived. The company announced that it would cut more than 10 percent of its 43,000-person work force--roughly 4,800 jobs. Many positions being axed are related to operations, such as human resources, information technology and finance. Manufacturing will also take a serious hit; already the company has announced that it's closing a packaging facility in Colon, Panama, plus manufacturing facilities in Mayaguez, Puerto Rico, and Barcelona. So far, 1,300 employees have been given notice and an additional 3,500 workers will be cut by the end of the year.

According to the company's announcement, the cuts are part of BMS's overall strategy to "transform the company...into a next-generation BioPharma company that pairs the scale and resources of a mid-sized pharmaceutical company with the entrepreneurial spirit and innovative focus of a biotech startup." Sound familiar? BMS is divesting itself of its Massachusetts-based medical imaging division; it's also reviewing "strategic alternatives" for ConvaTec and Mead Johnson, two other nonpharmaceutical divisions.

- see this release from BMS on the cuts and restructuring
- read the New York Times article for more

ALSO: Take a look at BMS's pipeline. Report

Related Articles:
BMS starts laying off workers. Report
BMS to unveil (big?) layoffs. Report
Bristol CEO: Job cuts, shutdowns continue. Report
Cornelius get big payday for BMS temp job. Report

Suggested Articles

Genor Biopharma banked $160 million from the likes of Hillhouse and Temasek Holdings to advance its clinical-stage autoimmune and cancer programs.

Going from being the CSO of Bristol Myers Squibb to running one of the biggest cancer research organizations in the world is a major career shift.

Hahn made the commitment in a speech that called on the FDA to learn from the crisis to enact lasting policies that accelerate drug development.